A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SYSTEMICALLY ADMINISTERED INTERFERON-ALPHA, INTERFERON-BETA, OR INTERFERON-GAMMA IN COMBINATION WITH CRYOTHERAPY FOR THE TREATMENT OF CONDYLOMA-ACUMINATUM

被引：23

作者：

BONNEZ, W

OAKES, D

BAILEYFARCHIONE, A

CHOI, A

HALLAHAN, D

PAPPAS, P

HOLLOWAY, M

COREY, L

BARNUM, G

DUNNE, A

STOLER, MH

DEMETER, LM

REICHMAN, RC

机构：

[1] UNIV ROCHESTER, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY USA

[2] UNIV ROCHESTER, DEPT BIOSTAT, ROCHESTER, NY USA

[3] UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA

[4] UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA

[5] UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA USA

[6] CLEVELAND CLIN, DEPT PATHOL, CLEVELAND, OH USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 1995年 / 171卷 / 05期

关键词：

D O I：

10.1093/infdis/171.5.1081

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

One hundred fifty-two patients were enrolled in a study to evaluate 3 interferon (IFN) preparations used in combination with cryotherapy for treatment of anogenital warts. Subjects received subcutaneous injections (2 X 10(6) units/m(2)) of IFN-alpha n1, -beta, -gamma or placebo 3 times a week for 6 weeks and cryotherapy with liquid nitrogen. Subjects were followed less than or equal to 1 year, Among patients followed greater than or equal to 12 weeks, two-thirds had a complete response. No significant differences in rates of complete response (P = .37) or reappearance of a wart at the initial site (P = .20) were noted among the treatment groups, However, patients who received IFN-beta or -gamma developed new warts at a significantly lower frequency (P = .02), IFN administration was associated with side effects but was well tolerated. IFN-beta was the least toxic of the 3 preparations and had the best therapeutic ratio.

引用

页码：1081 / 1089

页数：9

共 37 条

[1] Oriel D., Genital human papillomavirus infection, Sexually Transmitted Diseases, pp. 433-441, (1990)
[2] Becker T.M., Stone K.M., Alexander E.R., Genital human papillomavirus infection. A growing concern, Obstet Gynecol Clin North Am, 14, pp. 389-396, (1987)
[3] Kling A.R., Genital warts—therapy, Semin Dermatol, 11, pp. 247-255, (1992)
[4] Ling M.R., Therapy of genital human papillomavirus infection. Ii: Methods of treatment, Int J Dermatol, 31, pp. 769-776, (1992)
[5] MMWR Morb Mortal Wkly Rep, 42, pp. 1-101, (1993)
[6] Baron S., Tyring S.K., Fleischmann W.R., Et al., The interferons. Mechanisms of action and clinical applications, JAMA, 266, pp. 1375-1383, (1991)
[7] Vance J.C., Bart B.J., Hansen R.C., Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris, Arch Dermatol, 122, pp. 272-277, (1986)
[8] Eron L.J., Judson F., Tucker S., Et al., Interferon therapy for condylomata acuminata, N Engl J Med, 315, pp. 1059-1064, (1986)
[9] Friedman-Kien A., Eron L.J., Conant M., Et al., Natural interferon alpha for treatment of condylomata acuminata, JAMA, 259, pp. 533-538, (1988)
[10] Reichman R.C., Oakes D., Bonnez W., Et al., Treatment of condyloma acuminatum with three different interferons administered intrale-sionally: A double-blind, placebo-controlled trial, Ann Intern Med, 108, pp. 675-679, (1988)

← 1 2 3 4 →